 |
Clinical and Developmental Advisory Board
Jeffrey Cummings, M.D. (UCLA)
Dr. Cummings is the Augustus S. Rose Professor of Neurology and is also Professor of Psychiatry and Biobehavioral Sciences at UCLA. Dr. Cummings is Founder and Director of the UCLA Alzheimer’s Disease Center. The Center has an active clinical trials program and fosters imaging, genetics, clinical and neuroscience research. Dr. Cummings is Director of the UCLA Behavioral Neuroscience and Dementia Research Fellowship. Many of the approximately 40 fellows that he has trained currently hold leadership positions in dementia programs throughout the United States and the world. He is the Founder and Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. Dr. Cummings’ interests embrace clinical trials and the development of new treatments for neurodegenerative disorders and other neurological diseases. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association and in 2005 was named Edward Henderson State-of-the-Art Lecturer by the American Geriatrics Society. Dr. Cummings has authored or edited 20 books and over 450 peer reviewed papers. He has broad interests in dementing disorders, neuropsychiatry, neurotherapeutics, and the interface of neuroscience and society.
Peter Jeffrey Snyder, Ph.D. (University of Connecticut, Pfizer)
Dr. Snyder received his doctorate in clinical psychology and behavioral neuroscience, from Michigan State University in 1992, following an internship in clinical neuropsychology at the Long Island Jewish Medical Center (New York, USA). Dr. Snyder received a Wilder Penfield Research Fellowship in 1992 from the Epilepsy Foundation of America, and he served as a Clinical Neurosciences Fellow in the NIMH Clinical Research Center for the Study of Schizophrenia at Hillside Hospital (Albert Einstein College of Medicine) in 1992 and 1993. He serves as an Associate Editor of Brain and Cognition, and he has delivered over 100 presentations at international scientific conferences. From 1998 to 2005, Dr. Snyder was employed as a scientist, clinician and manager at Pfizer Global Research & Development – Groton Laboratories (Connecticut, USA) – the largest research laboratory of Pfizer, Inc. Dr. Snyder was responsible for the identification and development of novel clinical technologies for the CNS therapeutic area at Pfizer. Then, as a Director and Early Clinical Leader, Dr. Snyder led the early clinical development of novel compounds for the treatment of schizophrenia and Alzheimer’s disease at Pfizer, Inc. Dr. Snyder left Pfizer in late 2005, to return to academia as a Professor (with tenure) in the Department of Psychology at the University of Connecticut (Storrs, CT). Dr. Snyder teaches graduate courses in cognitive neuroscience and clinical neuropsychology, he maintains an active laboratory, and he serves as the major professor for several graduate and post-doctoral students. Dr. Snyder consults to several private corporations, and he is an active adjunct faculty member in the Yale Child Study Center, Yale University School of Medicine.
Michael Knable, D.O. (George Washington University, Bethesda Behavioral Sciences)
Michael Knable is President of Bethesda Behavioral Sciences, a consulting firm focused on the development of central nervous system disorder therapies. Formerly, Dr. Knable held positions as Executive Director of the Stanley Medical Research Institute, the largest private agency providing funds for schizophrenia and bipolar disorder research, and at the National Institute of Mental Health. Dr. Knable has authored more than 60 publications on the neuroimaging, neuropathology, and pharmacology of neuropsychiatric disease and is Assistant Clinical Professor of Psychiatry at the George Washington University Medical School and Adjunct Professor of Psychiatry at the Uniformed Services University of the Health Sciences.
Herbert Y. Meltzer, M.D. (Vanderbilt, Centerstone Mental Heath, NARSAD, IPAP)
Herbert Y. Meltzer is Bixler/May/Johnson Professor of Psychiatry and Pharmacology and Director of the Psychobiology Program for Translational Research at the Vanderbilt University School of Medicine, in Nashville, Tennessee. He is also Director of the Schizophrenia Program of Centerstone Mental Health System in Nashville, and chair of the Young Investigator Grant Review Committee for NARSAD. He is chairman of the International Psychopharmacology Algorithm Project (www.IPAP.org). Dr. Meltzer received his BA from Cornell University, an MA in Chemistry from Harvard, and his MD from Yale University. Dr. Meltzer has been President of the American College of Neuropsychopharmacology (ACNP) and the Collegium International Neuro-psychopharmacologicum (CINP). He served as editor of Psychopharmacology: The Third Generation of Progress and co-editor of the ACNP journal, Neuropsychopharmacology, and is a member of the editorial board of numerous scientific journals. Dr. Meltzer is the recipient of the Efron and Paul Hoch Awards of the ACNP, the Noyes Prize of the Commonwealth of Pennsylvania, the Edward J. Sachar Award from Columbia University, the Lieber Prize for Schizophrenia Research from NARSAD, the Stanley Dean Award for Research in Schizophrenia of the American College of Psychiatry, the Gold Medal Award of the Society of Biological Psychiatry, the Earl Sutherland Prize for Achievement in Research of Vanderbilt University (2004), the Research Prize of the American Psychiatric Association (2005), and the Grant Liddle Award for Clinical Research from Vanderbilt University (2008).His research interests include: clinical and basic psychopharmacology, with an emphasis on antipsychotic drug efficacy, safety and tolerability, the mechanism of action of antipsychotic drugs, genetic factors in schizophrenia and pharmacogenomics, prevention of suicide in schizophrenia, and cognitive impairment in schizophrenia.
Christopher F. O’Brien, M.D. (Neurocrine Biosciences, Inc, San Diego)
Dr. O’Brien is Sr. Vice President Clinical Development at Neurocrine Biosciences and Associate Professor (Voluntary), Department of Neuroscience, University of California San Diego. He has been active as an Investigator in clinical research in neurodegenerative disorders (e.g., Huntington’s Disease, Parkinson’s Disease) within Academic and Industry settings for more than 15 years. His primary interest is the clinical development of new therapies for unmet medical needs.
James G. Ottinger, R.Ph. (Premier Research Group, Horsham, Pennsylvania)
James Ottinger is Vice President of Regulatory Affairs at Premier Research and is responsible for regulatory strategy and operations. Premier Research is a Clinical Research Organization with specific expertise in drug development in the areas of neurological and psychiatric disorders, pain and inflammation, and oncology. Mr. Ottinger has over 20 years of regulatory experience from Premier Research, SCIREX Corporation, and Wyeth Research, where he was responsible for global regulatory programs in Alzheimer’s disease, anxiety disorders, bipolar disorders, major depression, multiple sclerosis, neuropathic pain, schizophrenia and stroke.
Michael G. Palfreyman, Ph.D., D.Sc., MRPharmS. (ChemDiv)
Michael G. Palfreyman is currently Head, Translational R&D at ChemDiv, Inc. and is responsible for the integration of drug development and clinical studies. In addition he is responsible for R&D Diligence at Torrey Pines Investment. Since 2009, Michael has been Executive Program Director and Senior Scientific Advisor to EnVivo Pharmaceuticals. Previously, Michael was VP, Program Management & Product Development at EnVivo Pharmaceuticals where he was responsible for the late stage discovery and preclinical development of two CNS drugs now demonstrating efficacy in clinical testing. In addition, Michael is Senior Scientific Advisor to Vitruvean, LLC., a drug discovery technology company developing neurodegenerative disease models in Drosophila. Michael is a seasoned leader in the biotechnology and pharmaceutical industries with over 35 years experience. In 2003, he co-founded NOVACE Corporation, a network of entrepreneurs providing scientific and strategic management solutions to the biotechnology industry and venture capital community, and from 2000 - 2003, he was Founder, President and Chief Scientific Officer of Psychiatric Genomics, a biotechnology company developing genome-based approaches to drug discovery for the treatment of Mental Illness. He was SVP of Research & Development at Scriptgen (Anadys) Pharmaceuticals, a biotechnology company specializing in genomic-based drug discovery in infectious diseases, and before that, Michael held a number of executive positions at Marion Merrell Dow Research Institute (Sanofi-Aventis), including Head of CNS Research, Director of Pharmacological Sciences, Co-Chair Pipeline Evaluation Team, Vice President Global Biological and Scientific Affairs, Vice President Research, North America and Member of the Research & Development Executive Management Team. His own research included discovery and development of a number of psychotherapeutic compounds for treatment of psychosis, depression, stroke, epilepsy, emesis, Parkinson’s, and Alzheimer’s diseases. Many of these compounds have entered clinical development and a number have reached the marketplace. From 1970 to 1975 Michael was Head of Biochemical Pharmacology at Beecham Pharmaceuticals (GlaxoSmithKline) where he pioneered rational biochemical approaches to drug discovery with three compounds demonstrating clinical effectiveness. Michael received his B.Pharm, MRPharmS, Ph.D. and D.Sc. from the University of Nottingham in pharmacy, neuroscience and rational drug design of CNS active drugs, respectively. He has been an invited speaker and chairperson for a number of international and national conferences, is co-inventor on 35 issued US patents, 3 pending patents and co-author of over 150 scientific articles and book chapters.
Leslie Patmore, Ph.D. (Syntex, Quintiles, Aptuit)
Dr. Leslie Patmore is currently Managing Director of Aptuit Consulting Inc., the consulting division of Aptuit, a global drug development services company. Areas of consulting include drug development strategy, execution and safety assessment with particular expertise in QT prolongation. Until October 2005, Dr. Patmore was Vice President of the Preclinical Sciences and Pharmaceutical Analysis operations at Quintiles’ European pharmaceutical development centre in Edinburgh and worked for Quintiles for 10 years in various management positions. Dr Patmore has a B.Sc. and Ph.D. in Physiology and Biophysics and over 25 years of experience in pharmaceutical research and development. Previously at Syntex Pharmaceuticals for 15 years and with Roche briefly following the acquisition of Syntex in 1995, he has held positions in discovery research, safety assessment and as a leader of drug development programs. Actively involved in basic science and pharmaceutical R&D scientific societies, Dr. Patmore is a regular speaker at international opinion forming conferences and has particular interests in targets for new therapeutic entities and safety of drugs relating to proarrhythmic risk. Dr. Patmore holds an Honorary Research Fellowship in the Department of Medicine at Edinburgh University and serves as a Board Director of the Safety Pharmacology Society.
Thomas Thompson, Ph.D. (Quintiles, Hoechst Marion Roussel)
Dr. Thompson is the head of R&D Services, a pharmaceutical consulting firm specializing in preclinical and early clinical development. He has 24 years experience in the pharmaceutical industry in the fields of preclinical and clinical ADME, pharmacokinetics and drug metabolism, and has worked in the Pharma, CRO and consulting sectors. Dr. Thompson has published and presented widely in the areas of animal and human ADME, pharmacokinetics, drug metabolism and drug interactions.
James White, Ph.D. (CoLucid)
Dr. White received his Ph.D. in Pharmacology and Toxicology from Purdue University. Following completion of his work at Purdue, Dr. White joined Eli Lilly and Company as a Senior Toxicologist, where he was responsible for the toxicological evaluation of several new drugs targeted for cardiovascular disease, central nervous system disorders and cancer. Over a 20 year career at Lilly, Dr. White held several senior management positions in the company’s central nervous system drug discovery and development divisions. In 2001, Dr. White joined Hypnion, Inc., a biotech company in the Boston-area as Executive Vice President of Research and Development and Chief Operating Officer. In that role, he led a multi-disciplinary team to discover and develop new non-addicting sleep and wake promoting medications. He joined CoLucid as President and CEO in 2006. Dr. White also serves as a member of the Board of Directors of CoLucid.
|
